Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-03-14Clinical Trial Update: Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up [Phase 4]
Phase 4 study reporting 3-year follow-up results comparing aripiprazole, quetiapine, and ziprasidone for first-episode psychosis.
-
CLINICAL_TRIALS trial_result · 2017-03-14Clinical Trial Update: Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis [Phase 4]
Phase 4 trial comparing aripiprazole, quetiapine, and ziprasidone in first-episode nonaffective psychosis has completed.
-
CLINICAL_TRIALS trial_result · 2017-03-14Clinical Trial Update: Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up [Phase 4]
Phase 4 follow-up study evaluating neurocognitive outcomes in the treatment of first-episode non-affective psychosis over 1 year.
-
CLINICAL_TRIALS trial_result · 2017-03-14Clinical Trial Update: Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia [NA]
A ClinicalTrials.gov entry indicates the Family-Directed Cognitive Adaptation Program for individuals with schizophrenia has completed its s…
-
CLINICAL_TRIALS research · 2017-03-13Clinical Trial Update: The Immune System and Psychiatric Disorders
The update summarizes a completed clinical trial investigating potential links between the immune system and several psychiatric disorders, …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-03-10Clinical Trial Update: Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia [Phase 2]
A Phase 2 trial update reports on receptor occupancy of ITI-007 (lumateperone) using PET in stable schizophrenia; the study has been complet…
-
CLINICAL_TRIALS trial_result · 2017-03-10Clinical Trial Update: Real Life Assessment of Abilify Maintena
A real-life assessment trial of Abilify Maintena (aripiprazole long-acting injectable) for schizophrenia was terminated.
-
CLINICAL_TRIALS trial_result · 2017-03-09Clinical Trial Update: Integration of Illness Management and Recovery Within ACT [NA]
A completed clinical trial update describes integrating Illness Management and Recovery within Assertive Community Treatment for individuals…
-
CLINICAL_TRIALS trial_result · 2017-03-06Clinical Trial Update: Computerized Cognitive-Behavioral Therapy for Auditory Hallucinations [NA]
This clinical trial update notes the completion of a study evaluating computerized cognitive-behavioral therapy for auditory hallucinations …
-
CLINICAL_TRIALS trial_result · 2017-03-03Clinical Trial Update: Effects of RG1068 (Secretin) on Information Processing in Schizophrenia [Phase 2]
Phase 2 clinical trial update evaluating RG1068 (Secretin) for information processing in schizophrenia; the trial has completed.
-
CLINICAL_TRIALS trial_result · 2017-03-01Clinical Trial Update: Transcranial Direct Current Stimulation (tDCS) and Hallucinations in Schizophrenia [NA]
A completed clinical trial assessed transcranial direct current stimulation as a treatment for auditory hallucinations in schizophrenia.
-
FDA approval · 2017-02-23FDA Approved: FANAPT — Supplemental Application (Vanda Pharmaceuticals Inc.)
The FDA approved a supplemental application for Fanapt (iloperidone) submitted by Vanda Pharmaceuticals Inc.
-
FDA approval · 2017-02-23FDA Approved: ABILIFY MAINTENA — Supplemental Application (Otsuka America Pharmaceutical, Inc.)
FDA approved a supplemental application for ABILIFY MAINTENA (aripiprazole) submitted by Otsuka America Pharmaceutical, Inc., for the long-a…
-
FDA approval · 2017-02-23FDA Approved: FLUPHENAZINE DECANOATE — Supplemental Application (Endo USA, Inc.)
The FDA approved a supplemental application for Fluphenazine Decanoate by Endo USA, Inc.
-
FDA approval · 2017-02-23FDA Approved: PERPHENAZINE — Supplemental Application (Endo USA, Inc.)
FDA approved a supplemental application for Perphenazine by Endo USA, Inc., updating the drug's approval status and/or labeling.
-
FDA approval · 2017-02-23FDA Approved: PROCHLORPERAZINE MALEATE — Supplemental Application (Jubilant Cadista Pharmaceuticals Inc.)
The FDA approved a supplemental application for Prochlorperazine maleate by Jubilant Cadista Pharmaceuticals Inc.
-
FDA approval · 2017-02-23FDA Approved: ZYPREXA INTRAMUSCULAR — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for ZYPREXA INTRAMUSCULAR (olanzapine) from Eli Lilly and Company, adding the intramuscular formulat…
-
FDA approval · 2017-02-23FDA Approved: ZYPREXA ZYDIS — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for ZYPREXA ZYDIS (olanzapine) from Eli Lilly and Company.
-
FDA approval · 2017-02-23FDA Approved: RISPERIDONE — Supplemental Application (Janssen Pharmaceutical, Inc.)
FDA approved a supplemental application for Risperidone submitted by Janssen Pharmaceutical, Inc. The action pertains to an addition or modi…
-
FDA label_change · 2017-02-23FDA Approved: RISPERDAL — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Risperdal (risperidone) from Janssen Pharmaceuticals, resulting in changes to the product la…
-
FDA approval · 2017-02-23FDA Approved: INVEGA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVEGA (paliperidone) from Janssen Pharmaceuticals, Inc.
-
FDA approval · 2017-02-23FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Geodon (ziprasidone) submitted by Viatris Specialty LLC. This action relates to an approved supp…
-
FDA approval · 2017-02-23FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Geodon (ziprasidone) submitted by Viatris Specialty LLC.
-
FDA approval · 2017-02-23FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Patriot Pharmaceuticals LLC)
The FDA approved a supplemental application for haloperidol decanoate from Patriot Pharmaceuticals LLC, representing an augmentation to the …
-
FDA approval · 2017-02-23FDA Approved: SEROQUEL XR — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approved a supplemental application for SEROQUEL XR (quetiapine) from AstraZeneca Pharmaceuticals LP, updating or expanding its labeling…